Neurochemical pathogenesis of fibromyalgia syndrome

Journal of Musculoskeletal Pain

Volumn 4, Issue 1-2, 1996, Pages 61-92

  Russell, I Jon ^a  

^a Mays Cancer Center at UT Health San Antonio   (United States)

Author keywords

adenosine triphosphate ATP ; allodynia; calcitonin gene related peptide CGRP ; Fibromyalgia; pathogenesis; serotonin; substance P

Indexed keywords

ADENOSINE TRIPHOSPHATE; CALCITONIN GENE RELATED PEPTIDE; SEROTONIN; SUBSTANCE P;

ALLODYNIA; FIBROMYALGIA; HUMAN; NERVE STIMULATION; NEUROTRANSMISSION; NOCICEPTION; PAIN ASSESSMENT; PATHOGENESIS; REVIEW;

EID: 0029978024     PISSN: 10582452     EISSN: None     Source Type: Journal    
DOI: 10.1300/J094v04n01_06     Document Type: Review

References (70)

1. Wolfe F, Smythe HA, Yunus MB, Bennett RM, Bombardier C, Goldenberg DL, Tugwell P, Campbell SM, Abeles M, Clark P, Fam AG, Farber SJ, Fiechtner JJ, Franklin CM, Gatter RA, Hamaty D, Lessard J, Lichtbroun AS, Masi AT, McCain GA, Reynolds WJ, Romano TJ, Russell IJ, Sheon RP: The American College of Rheumatology 1990 Criteria for the Classification of Fibromyalgia. Arthritis Rheum 33:160-172,1990.
2. Wolfe F, Ross K, Anderson J, Russell IJ: Aspects of fibromyalga in the general population: sex, pain threshold, and fibromyalgia symptoms. J Rheumatol 21(1):151-6,1995.
3. Wolfe F, Ross K, Anderson J, Russell IJ, Hebert L: The prevalence and characteristics of fibromyalgia in the general population. Arthritis Rheum 38:19-28,1995.
4. Malmberg A, Yaksh T: Hyperalgesia mediated by spinal glutamate or substance P receptor blocked by spinal cyclooxygenase inhibition. Science 257: 1276-1279,1992.
5. Skilling SR, Smullin DH, Larson AA: Differential effects of C- and N-terminal substance P metabolites on the release of amino acid neurotransmitters from the spinal cord: potential role in nociception. Journal of Neuroscience 10: 1309-1318,1990.
6. Igwe OJ, Sun X, Larson AA: Role of substance P amino terminal metabolites in substance P-induced desensitization in mice. Neuroscience 36:535-542, 1990.
7. Larson AA, Igwe OJ, Seybold VS: Effects of lysergic acid diethylamide (LSD) and adjuvant-induced inflammation on desensitization to and metabolism of substance P in the mouse spinal cord 55108. Pain 37:365-373,1989.
8. Raffa RB, Friderichs E, Reimann W, Shank RP, Codd EE, Vaught JL: Opioid and nonopioid components independently contribute to the mechanism of action of tramadol, an 'atypical' opioid analgesic. J Pharm Exp Therapeutics 260: 275-285,1992.
9. Naranjo JR, Arnedo A, Molinero MT, Del Rio J: Involvement of spinal monoaminergic pathways in antinocicpetion produced by substance P and neurotensin in rodents. Neuropharm 260:291-298,1989.
10. Eide PK, Hole K: Interactions between serotonin and substance P in the spinal regulation of nociception. Brain Res 550:225-230,1991.
11. Moldofsky H, Warsh JJ: Plasma tryptophan and musculoskeletal pain in nonarticular rheumatism ("fibrositis syndrome"). Pain 5:65-71,1978.
12. Moldofsky H: Rheumatic pain modulation syndrome: The interrelationships between sleep, central nervous system, serotonin and pain. Adv Neurol 33: 51-57,1982.
13. Russell IJ: Neurohormonal: Abnormal laboratory findings related to pain and fatigue in fibromyalgia. J Musculoske Pain 3(2):59-65, 1995.
14. Beetham WP, Jr.: Diagnosis and management of fibrositis syndrome and psychogenic rheumatism. Med Clin North Am 63:433-439, 1979.
15. Yunus MB, Dailey JW, Aldag JC, Masi AT, Jobe PC: Plasma tryptophan and other amino acids in primary fibromyalgia: A controlled study. J Rheumatol 19:90-94, 1992.
16. Russell IJ, Michalek JE, Vipraio GA, Fletcher EM, Javors MA, Bowden CA: Platelet 3H-imipramine uptake receptor density and serum serotonin levels in patients with fibromyalgia/fibrositis syndrome. J Rheumatol 19:104-109, 1992.
17. Hrycaj P, Stratz T, Muller W: Platelet 3H-imipramine uptake receptor density and serum serotonin in patients with fibromyalgia/fibrositis syndrome. J Rheumatol 20:1986-1987,1993.
18. Klein R, Bansch M, Berg PA: Clinical relevance of antibodies against serotonin and gangliosides in patients with primary fibromyalgia syndrome. PsychoNeuro-Endocrinology 17:593-598,1992.
19. Russell IJ, Vodjani A, Michalek JE, Vipraio GA, Lopez Y, MacKillip F: Circulating antibodies to serotonin in fibromyalgia syndrome, rheumatoid arthritis, osteoarthrosis, and healthy normal controls. J Musculoske Pain 3 (Suppl #1): 143,1995 (Abstract).
20. Baba H, Kaune GC, Ilyas AA, Pestronk A, Cornblath DR, Chaudhry V, Griffin JW, Quarles RH: AntiGm1 ganglioside antibodies with differing fine specificities in patients with multifocal motor neuropathy. J Neuroimmunology 25: 143-150, 1989.
21. Russell IJ, Vipraio GA: Serotonin (5HT) in serum and platelets (PLT) from fibromyalgia patients (FS) and normal controls (NC). Arthritis Rheum 37 (Suppl): S214,1994.
22. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ: Protein measurement with the folin phenol reagent. J Biol Chem 1994.
23. Russell IJ, Fletcher EM, Michalek JE, McBroom PC, Hester GG: Treatment of primary fibrositis/fibromyalgia syndrome with ibuprofen and alprazolam. A double-blind, placebo-controlled study. Arthritis Rheum 34:552-560, 1991.
24. Chesney CM, Pifer DD, Cagen LM: Triazolobenzodiazepines competitively inhibit the binding of platelet activating factor [PAF] to human platelets. Biochem Biophys Res Commun 144:359-366,1987.
25. Buskila D, Gladman DD, Langevitz P, Urowitz S, Smythe HA: Fibromyalgia in HIV infection. J Rheumatol 17:1202-1206,1990.
26. Larsson M, Hagberg L, Norkrans G, Foreman A: Indole amine deficiency in blood and cerebrospinal fluid from patients with human immunodeficiency virus infection. J Neurosci Res 23:441-446,1989.
27. Anderson GM, Mefford IN, Tolliver TJ, Riddle MA, Ocame KM, Leckman JF, Cohen DJ: Serotonin in human lumbar cerebrospinal fluid: A reassessment. Life Sci 46:247-255,1990.
28. Russell IJ, Vaeroy H, Javors M, Nyberg F: Cerebrospinal fluid biogenic amine metabolites in fibromyalgia/fibrositis syndrome and rheumatoid arthritis. Arthritis Rheum 35:550-556,1992.
29. Houvenagel E, Forzy G, Leloire O, Gallois P, Hary S, Hautecoeur P, Convain L, Henniaux M, Vincent G, Dhondt JL: Cerebrospinal fluid monoamines in primary fibromyalgia. (French). Rev Du Rhumat Et Des Maladies Osteo-Articulaires 57:21-23,1990.
30. Houvenagel E, Forzy G, Cortet B, Vincent G: Hydroxy indolacetic acid in cerebrospinal fluid in fibromyalgia. Arthritis Rheum 33 (Suppl):S55,1990.
31. Russell IJ, Vipraio GA, Acworth I: Abnormalities in the central nervous system [CNS] metabolism of tryptophan [TRY] to 3-hydroxy kynurenine [OHKY] in fibromyalgia syndrome [FS]. Arthritis Rheum 36(9):S222,1993 (Abstract).
32. Ebert MH, Kartzinel R, Cowdry RW, Goodwin FK: Cerebrospinal fluid amine metabolites and the probenecid test. In: Neurobiology of cerebrospinal fluid. Edited by JH Wood. Plenum Press, New York, 1980.
33. Russell IJ, Brown RR: Serum tryptophan and kynurenine in fibromyalgia syndrome, rheumatoid arthritis, osteoarthritis, and healthy normal controls. Arthritis Rheum 36(9):S223,1993.
34. Russell IJ, Michalek JE, Vipraio GA, Fletcher EM, Wall K: Serum amino acids in fibrositis/fibromyalgia syndrome. J Rheumatol 19 (Suppl):158-163,1989.
35. Brown RR, Ozaki Y, Datta SP, Borden EC, Sondel PM, Malone DG: Implications of interferon-induced tryptophan catabolism in cancer, autoimmune diseases and AIDS. Adv Exp Med Biol 294:425-435,1991.
36. Aune TM, Pogue SL: Inhibition of tumor cell growth by interferon-gamma is mediated by two distinct mechanisms dependent upon oxygen tension: Induction of tryptophan degradation and depletion of intracellular nicotinamide adenine dinucleotide. J Clin Invest 84:863-875,1989.
37. Burnet PWJ, Mefford IN, Smith CC, Gold PW, Sternberg EM: Hippocampal 8-[3H]hydroxy-2-(di-n-propylamino)tetralin binding site densities, serotonin receptor (5HT1A) messenger ribonucleic acid abundance, and serotonin levels parallel the activity of the hypothalamopituitary-adrenal axis in rat. J Neurochem 59:1062-1070,1992.
38. Crofford LJ, Pillemer SR, Kalogeras KT, Cash JM, Michelson D, Kling MA, Sternberg EM, Gold PW, Chrousos GP, Wilder RL: Hypothalamic-pituitary-adrenal axis perturbations in patients with fibromyalgia. Arthritis Rheum 37: 1583-1592,1994.
39. Bennett RM, Clark SR, Campbell SM, Burckhardt CS: Low levels of somatomedin C in patients with the fibromyalgia syndrome: A possible link between sleep and muscle pain. Arthritis Rheum 35:1113-1116,1992.
40. Bennett RM, Clark SR, Burckhardt CS, Cook D: IGF-1 assays and other GH tests in 500 fibromyalgia patients. J Musculoske Pain 3 (Suppl #1):109,1995 (Abstract).
41. Russell IJ, Vipraio GA, Michalek J, Lopez YG: Insulin-like growth factor (IGF1) in fibromyalgia, rheumatoid arthritis, osteoarthritis and healthy normal controls: Roles of diagnosis, age, sex and ethnic origin. Arthritis Rheum 35 (Suppl):S160,1992 (Abstract).
42. Bennett RM, Clark SR, Burckhardt CS, Walczyk J: A double-blind placebo-controlled study of growth hormone therapy in fibromyalgia. J Musculoske Pain 3 (Suppl #1):110,1995 (Abstract).
43. Walker PD, Riley LA, Hart RP, Jonakait GM: Serotonin regulation of tachykinin biosynthesis in the rat neostriatum. Brain Res 546:33-39,1991.
44. Murphy RM, Zemlan FP: Differential effects of substance P on serotonin-modulated spinal nocideptive reflexes. Psychopharm (Berlin) 93:118-121,1987.
45. Sharma HS, Nyberg F, Olsson Y, Dey PK: Alteration of substance P after trauma to the spinal cord: An experimental study in the rat. Neurosci 38: 205-212,1990.
46. Maimberg AB, Yaksh TL: Hyperalgesia mediated by spinal glutamate or substance P receptor blocked by spinal cyclooxygenase inhibition. Science 257:1276-1279,1992.
47. Reynolds WJ, Chiu B, Inman RD: Plasma substance P levels in fibrositis. J Rheumatol 15:1802-1803,1988.
48. Vaeroy H, Helle R, Forre O, Kass E, Terenius L: Elevated CSF levels of substance P and high incidence of Raynaud's phenomenon in patients with fibromyalgia: New features for diagnosis. Pain 32:21-26,1988.
49. Russell IJ, Orr MD, Littman B, Vipraio GA, Alboukrek D, Michalek JE, Lopez Y, MacKillip F: Elevated cerebrospinal levels of substance P in patients with the fibromyalgia syndrome. Arthritis Rheum 37:1593-1601,1994.
50. Welin M, Bragee B, Nyberg F, Kristiansson M: Elevated substance P levels are contrasted by a decrease in met-enkephalin-arg-phe levels in CSF from fibromyalgia patients. J Musculoske Pain 3 (Suppl #1):4,1995 (Abstract).
51. Nyberg F, Liu Z, Lind C, Thornwall M, Ordeberg G: Enhanced CSF levels of substance P in patients with painful arthrosis but not in patients with pain from herniated lumbar discs. J Musculoske Pain 3 (Suppl #1):2,1995 (Abstract).
52. Almay BG, Johansson F, von Knorring L, Le Greves P, Terenius L: Substance P in CSF of patients with chronic pain syndromes. Pain 33:3-9,1988.
53. Cramer H, Rosler N, Rissler K, Gagniew MC, Renaud B: Cerebrospinal fluid immunoreactive substance P and somatostatin in neurological patients with peripheral and spinal cord disease. Neuropeptides 12:119-124,1988.
54. Gislason T, Hedner J, Terenius L, Bisette G, Nemeroff CB: Substance P, thyrotropin-releasing hormone, and monoamine metabolites in cerebrospinal fluid in sleep apnea patients. Am Rev Resp Dis 146:784-786,1992.
55. Tsigos C, Diemel LT, Tomlinson DR, Young RJ: Cerebrospinal fluid levels of substance P and calcitonin-gene-related peptide: Correlation with sural nerve levels and neuropathic signs in sensory diabetic polyneuropathy. Clinical Sci 1995.
56. Paik M: A graphic representation of a three-way contingency table: Simpson's paradox and correlation. American Statistician 39:53-54,1985.
57. Yukhananov RYu, Larson AA: An N-terminal fragment of substance P, substance P(1-7), down-regulates neurokinin-1 binding in the mouse spinal cord. Neurosci 178:163-166,1994.
58. Hornfeldt CS, Sun X, Larson AA: The NH2-terminus of substance P modulates NMDA-induced activity in the mouse spinal cord. J Neurosci 14: 3364-3369,1994.
59. 1-7) in fibromyalgia syndrome cerebrospinal fluid. J Musculoske Pain 3 (Suppl #1):5,1995.
60. Tamatani M, Senba E, Tohyama M: Calcitonin gene-related peptide- and substance P-containing primary afferent fibers in the dorsal column of the rat. Brain Res 495:122-130,1989.
61. McNeill DL, Westlund KN, Coggeshall RE: Peptide immunoreactivity of unmyelinated primary afferent axons in rat lumbar dorsal roots. J Histochem Cytochem 37:1047-1052,1989.
62. NcNeill DL, Chung K, Carlton SM, Coggeshall RE: Calcitonin gene-related peptide immunostained axons provide evidence for fine primary afferent fibers in the dorsal and dorsolateral funiculi of the rat spinal cord. J Comp Neurol 272:303-308,1988.
63. Martensson B, Nyberg S, Toresson G, Brodin E, Bertilsson L: Fluoxetine treatment of depression. Clinical effects, drug concentrations and monoamine metabolites, and N-terminally extended substance P in cerebrospinal fluid. Acta Psych Scand 79:586-596,1989.
64. Vaeroy H, Sakurada T, Forre O, Kass E, Terenius L: Modulation of pain in fibromyalgia (fibrositis syndrome): cerebrospinal fluid (CSF) investigation of pain related neuropeptides with special reference to calcitonin gene-related peptide (CGRP). J Rheumatol 19 (Suppl): 94-97,1989.
65. Reynolds MD: The development of the concept of fibrositis. J Hist Med Allied Sci 38:5-35,1983.
66. Layfer L: Fibromyalgia (fibrositis). Int Med J 167:131-132,1985.
67. Giovengo SL, Russell IJ, Larson AA: Amino acids in cerebrospinal fluid of patients with fibromyalgia. J Musculoske Pain 3 (Suppl #1):9,1995 (Abstract).
68. Eisinger J, Ayavou T: Transketolase stimulation in fibromyalgia. J Amer Coll Nutr 9:56-57,1990.
69. Eisinger J, Plantamura A, Ayavou T: Glycolysis abnormalities in fibromyalgia. J Amer Coll Nutr 13:144-148,1994.
70. Russell IJ, Vipraio GA: Red cell nucleotide abnormalities in fibromyalgia syndrome. Arthritis Rheum 36(9):S223,1993.